BLRX BioLineRx, Ltd.
14,950
$0.7183
$0.0383
(5.63%)
| Watchers | 14,950 |
| 52-Wk Low | $0.5528 |
| 52-Wk High | $2.53 |
| Market Cap | $54.36M |
| Volume | 232,814.00 |
| 52-Wk High | $2.53 |
| 52-Wk Low | $0.5528 |
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024PR Newswire • about 14 hours ago
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024...
Share to Feed
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting...
BioLineRx Announces $6 Million Registered Direct Offering BioLineRx Announces $6 Million Registered Direct Offering PR Newswire TEL AVIV, Israel, April 1, 2024 TEL AVIV, Israel, April 1, 2024...
BioLineRx Ltd. (NASDAQ:BLRX - Free Report) - Stock analysts at HC Wainwright lowered their FY2024 earnings estimates for BioLineRx in a report issued on Tuesday, March 26th. HC Wainwright analyst...
BioLineRx Ltd. (NASDAQ:BLRX - Free Report) - Equities researchers at HC Wainwright issued their Q1 2024 earnings estimates for BioLineRx in a report released on Tuesday, March 26th. HC Wainwright...
HC Wainwright reiterated their buy rating on shares of BioLineRx (NASDAQ:BLRX Free Report) in a report issued on Tuesday morning, Benzinga reports. HC Wainwright currently has a $21.00 price...
BioLineRx (NASDAQ:BLRX Get Free Report) was upgraded by equities research analysts at StockNews.com to a sell rating in a report issued on Wednesday.
Separately, HC Wainwright...
BioLineRx Ltd. (NASDAQ:BLRX Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 324,700...
BioLineRx (NASDAQ:BLRX Get Free Report)s stock had its buy rating reiterated by HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently...
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire TEL AVIV, Israel...